Skip to main content
Dianthus Therapeutics, Inc. /DE/ logo

Dianthus Therapeutics, Inc. /DE/ — Investor Relations & Filings

Ticker · DNTH ISIN · US2528281080 LEI · 549300Z3N6ODPCOFC890 US Professional, scientific and technical activities
Open in API
Filings indexed 582 across all filing types
Latest filing 2026-05-22 Declaration of Voting R…
Country US United States of America
Listing US DNTH

About Dianthus Therapeutics, Inc. /DE/

https://dianthustx.com/

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company developing next-generation therapies for severe autoimmune diseases. The company engineers novel monoclonal antibodies with potentially best-in-class properties, focusing on proven mechanisms of action. Its lead candidate, claseprubart (DNTH103), is a potent and highly selective antibody targeting the active C1s complement protein. It is engineered with an extended half-life designed to allow for convenient, less frequent self-administered subcutaneous injections. The company's pipeline also includes DNTH212, a bifunctional inhibitor that targets Type 1 IFN suppression and B cell modulation. Dianthus aims to transform treatment for patients by developing therapies with the potential for improved clinical outcomes and greater convenience.

Recent filings

Filing Released Lang Actions
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 92% confidence The document is an SEC Form 8-K reporting Item 5.07: Submission of Matters to a Vote of Security Holders, including detailed vote counts for election of directors, advisory vote on executive compensation, and ratification of the auditors. This matches the definition for Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-05-22 English
8-K - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)
Earnings Release Classification · 95% confidence The document is a Form 8-K “Current Report” filed under Item 2.02 “Results of Operations and Financial Condition,” which furnishes the company’s earnings press release announcing quarterly financial results. This aligns with an initial announcement of quarterly/periodical financial results rather than the full financial statements. Therefore, it should be classified as an Earnings Release (ER). Q1 2026
2026-05-05 English
ARS - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)
Annual Report
2026-04-09 English
DEF 14A - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)
Proxy Solicitation & Information Statement
2026-04-09 English
4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)
Director's Dealing
2026-03-26 English
8-K - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, which is used for reporting unscheduled material events or corporate updates. The text mentions posting an updated corporate presentation on the company's website and includes a description of changes proposed to the FDA regarding clinical trial screening criteria. The document is relatively short (4164 characters) and primarily announces the availability of a corporate presentation (Exhibit 99.1) rather than containing the presentation itself or detailed financial data. According to the 'Menu vs Meal' rule, such announcements of report availability or presentations are classified as Regulatory Filings (RNS) rather than the report type itself. Therefore, the appropriate classification is Regulatory Filings (RNS).
2026-03-26 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.